Literature DB >> 12079564

Full-length HERV-H elements with env SU open reading frames in the human genome.

Patric Jern1, Mats Lindeskog, Damita Karlsson, Jonas Blomberg.   

Abstract

Human endogenous retroviruses (HERVs) are estimated to represent at least 1% of the human genome. An HERV-H env SU sequence (HERV-H19) was used to screen the high-throughput (htgs) and nonredundant (nr) databases for other HERV-H SU open reading frames (ORFs) and thus possible functional proteins. Using PCR with primers derived from HERV-H19 SU, we also obtained several new sequences with ORFs from a human DNA sample. In a phylogenetic analysis, ORF-containing sequences clustered with HERV-H sequences from chromosomes 1 and 2. SU ORF- and non-SU ORF-containing elements had about the same difference between 5' and 3' long terminal repeats (LTRs) (about 4%), indicating a similar time of integration. SU ORF sequences had a moderately high number of synonymous-versus-nonsynonymous mutations, which indicates a selection for maintenance of the HERV-H SU ORFs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079564     DOI: 10.1089/088922202760019383

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  2 in total

1.  Sequence variability, gene structure, and expression of full-length human endogenous retrovirus H.

Authors:  Patric Jern; Göran O Sperber; Göran Ahlsén; Jonas Blomberg
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

2.  Enhanced antitumoral activity of TLR7 agonists via activation of human endogenous retroviruses by HDAC inhibitors.

Authors:  David Díaz-Carballo; Sahitya Saka; Ali H Acikelli; Ekaterina Homp; Julia Erwes; Rebecca Demmig; Jacqueline Klein; Katrin Schröer; Sascha Malak; Flevy D'Souza; Adrien Noa-Bolaño; Saskia Menze; Emilio Pano; Swetlana Andrioff; Marc Teipel; Philip Dammann; Diana Klein; Amber Nasreen; Andrea Tannapfel; Nicole Grandi; Enzo Tramontano; Crista Ochsenfarth; Dirk Strumberg
Journal:  Commun Biol       Date:  2021-03-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.